Oxagen Spinout Atopix to Advance Allergy Pipeline
By Nuala Moran
Tuesday, June 4, 2013
LONDON A new company has been spun out of genomics pioneer Oxagen Ltd. to take forward the lead compound OC459 in fresh indications. The product has successfully completed Phase IIb development in asthma.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.